866-997-4948(US-Canada Toll Free)

Published on : Apr 29, 2014

The experimental dengue vaccine by Sanofi (SAN) has reportedly been found to be efficient in curtailing the effects of the mosquito-borne disease. This has brought the company a step closer to launching what could be the first inoculation against dengue. Figures from health care agencies show that dengue threatens nearly 50% of the world’s population.

The tests indicate that 56% of 10,275 children that were a part of the studies showed positive results. Sanofi, headquartered in Paris, said in a statement via e-mail. The early safety data from the study-which is in its late stages—are seen to be consistent with previously conducted trials, according to the company. 

However, there were no further details from Sanofi about the degree of protection offered by the vaccine against the four strains of the disease.

According to Olivier Charmeil, who heads the vaccines unit of Sanofi, these latest results have been achieved after over two decades of research and collaboration in dengue prevention.

In the past, there have been dengue outbreaks in the United States as well as Europe. This illness, which has symptoms akin to flu, has the potential of developing into a rare and fatal health condition where nose and gum bleeding, abdominal pain, and rapid short breathing occur.

The World Health Organization states that nearly 2.5 billion people worldwide face a risk from dengue, and nearly 500,000 people (many of whom are children) need to be hospitalized. The WHO also states that dengue causes death among 2.5% of the dengue-affected.